Moderna, Covid-19

Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna Stock Jumps on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Moderna Posts Unexpected Q3 Profit, Driven by Cost Cuts and Strong Covid Vaccine Sales
Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales. Moderna’s earnings per share and revenue surpassed Wall Street expectations, with earnings reaching a surprising profit and revenue exceeding projected figures.
Moderna’s stock pops after biotech ekes out profit and revenue beats by a wide margin
Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...
BioPharma Dive7h
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
The Boston Globe1d
Moderna sales get lift from early nod for newest COVID shot
Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...
Moderna’s Mixed Performance: Strong Spikevax Sales Drive Q3 Success Amid mRESVIA Uncertainties, Resulting in Hold Rating
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Moderna CEO Bancel steps down as sales chief, Bloomberg News reports
Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...
Moderna EPS Beats Estimates, Sales Rise
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Mixed Signals from Moderna’s Q3 2024 Performance: Hold Recommendation Issued
Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating on October 28. Joseph Stringer has ...
Moderna’s Bancel Steps Down as Sales Chief, Keeps CEO Role
Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.
BioPharma Dive1d
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date ...